Overview
- 45 inspections across 44 sites are on record.
- 138 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-05-15.
At a glance
Inspections
45
Sites
44
Observations
138
Career since
Apr 2021
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Emcure Pharmaceuticals Limited | 15 May 2026 | Human Drugs | On file |
| Zydus Lifesciences Limited | 5 May 2026 | Human Drugs | On file |
| Atlantic Analytical Laboratories LLC | 17 Mar 2026 | Human Drugs | On file |
| Eli Lilly and Company | 11 Feb 2026 | Human Drugs | On file |
| Anthea Pharma Private Limited | 22 Dec 2025 | Human Drugs | On file |
Sites inspected
Emcure Pharmaceuticals LimitedAhmedabad, India1 insp.
Zydus Lifesciences LimitedAhmedabad, India1 insp.
Atlantic Analytical Laboratories LLCWhitehouse, United States1 insp.
Eli Lilly and CompanyConcord, United States1 insp.
Anthea Pharma Private LimitedPashamylaram, India1 insp.
Co-investigators
Investigators who share inspections with this person.
Brandy N Lepage6 shared
Olumide A Akinyemi3 shared
Stephenie M Ortiz3 shared
Yvins Dezan3 shared
Suchan Kim2 shared
Anthony J Donato2 shared
Anastasia M Shields2 shared
Emmanuel T Donyina2 shared
Jogy George2 shared
Lata C Mathew2 shared
Full investigator report
Get the verbatim findings behind Jessica S Estriplet's 138 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site